Supporting opioid use disorder (OUD) patients on their road to recovery

Labcorp’s MAT urine drug testing helps to optimize appropriate care, including:

• Testing options that can be individualized based on the patient’s past use history, time in recovery and perceived risk of relapse
• Panels are designed to confirm compliance to OUD therapy and detect use of common illicit or prescribed controlled substances, including buprenorphine, norbuprenorphine and naloxone
• Results that address some of the variability inherent to urine drug testing (e.g., donor’s hydration status) and are normalized to the creatinine concentration in that urine sample
• The norbuprenorphine/buprenorphine (N/B) ratio, an additional interpretive dimension to MAT drug testing results

The value of the N/B ratio in Labcorp’s MAT Urine Drug Testing Program

By including the N/B ratio in MAT test results, Labcorp’s MAT testing panels can help:

• Improve buprenorphine compliance
• Detect buprenorphine “pill-dipping”
• Reduce buprenorphine misuse and potential diversion